ABSTRACT
Objectives Colonoscopy is considered a safe examination, serious complications being uncommon. Our study aimed to assess the adverse events of colonoscopy in a colorectal cancer screening programme with faecal immunochemical test (FIT) and to compare them with those of a previous programme with guaiac-based faecal occult blood test (gFOBT).
Design Retrospective observational study
Setting Population-based community-based colorectal cancer screening programme organised in Alsace, part of the national French programme, with FIT from 2015 to 2018 and gFOBT from 2003 to 2014.
Participants All residents aged 50 – 74 years having a colonoscopy performed for a positive FOBT.
Main outcome measures Adverse events were recorded through prospective voluntary reporting by community gastroenterologists and retrospective postal surveys addressed to persons screened.
Results Of 9576 colonoscopies performed for a positive FIT, 6194 (64.7%) were therapeutic. Overall, 180 adverse events were recorded (18.8‰, 95% CI 16.1-21.5), 114 of them (11.9‰, 95% CI 9.7-14.1) requiring hospitalisation, 55 (5.7‰, 95% CI 4.2-7.3) hospitalisation >24hrs, and 8 (0.8‰, 95% CI 0.3-1.4) surgery. The main complications requiring hospitalisation were perforation (n=18, 1.9‰, 95% CI 1.0-2.7) and bleeding (n=31, 3.2‰, 95% CI 2.1-4.4). We observed one death (1 / 27,000 colonoscopies). Overall, 52 persons harbouring at least one adenoma ≥ 10 mm were detected for one adverse event requiring hospitalisation >24hrs. The rate of adverse events remained stable between gFOBT and FIT programmes.
Conclusions The harms of colonoscopy in a colorectal cancer screening programme with FIT are more frequent than usually estimated, here six adverse events requiring hospitalisation >24hrs (three bleedings, two perforations), one necessitating surgery and 50 minor complications per 1000 colonoscopies. The price to be paid to save lives through colorectal cancer screening programmes is higher than what is stated in most pilots. Today, comparison between series dealing with colonoscopy-related adverse events is almost impossible.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was performed as part of a quality assurance programme within the CRC screening programme in Alsace without dedicated funding. The sources of funding of ADECA Alsace, the association in charge of the programme, include the French Sickness Fund (Assurance Maladie), the French Ministry of Health and the Haut-Rhin and Bas-Rhin Administrations (Conseils Départementaux du Haut-Rhin et du Bas-Rhin). They had no role in study design, data collection, analysis, and interpretation, or writing the report.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding This study was performed as part of a quality assurance programme within the CRC screening programme in Alsace without dedicated funding. The sources of funding of ADECA Alsace, the association in charge of the programme, include the French Sickness Fund (Assurance Maladie), the French Ministry of Health and the Haut-Rhin and Bas-Rhin Administrations (Conseils Départementaux du Haut-Rhin et du Bas-Rhin). They had no role in study design, data collection, analysis, and interpretation, or writing the report.
Ethical approval Not required.
Competing interests None declared
Data sharing statement All deidentified participant data are available upon reasonable request from IG isabelle.gendre{at}adeca-alsace.fr
Data Availability
All deidentified participant data are available upon reasonable request from IG isabelle.gendre@adeca-alsace.fr
Abbreviations
- AE
- adverse event
- ASGE
- American Society for Gastrointestinal Endoscopy
- CRC
- colorectal cancer
- ESGE
- European Society of Gastrointestinal Endoscopy
- FIT
- faecal immunochemical test
- gFOBT
- guaiac-based faecal occult blood test
- NHS BCSP
- National Health Service Bowel Cancer Screening Programme
- RCT
- randomised controlled trial